Fund II (2005)

NeoTract

NeoTract® is company focused on the unmet needs in Urology and has pioneered the development of UroLift™, a minimally invasive treatment designed to treat lower urinary tract symptoms due benign prostatic hypertrophy (BPH). 

BPH is one of the most common conditions impacting men over the age of 50 who suffer with lower urinary tract symptoms due to an enlarged prostate. NeoTract was cleared by the FDA in 2013 and acquired in 2017 by Teleflex.